Biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment.
Allogene Therapeutics, Inc., a dynamic player in immuno-oncology based in South San Francisco, California, focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. The company's innovative approach centers on UCART19, a promising allogeneic chimeric antigen receptor (CAR) T cell therapy designed for pediatric and adult patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia (ALL). Allogene is also advancing ALLO-501, an anti-CD19 allogeneic CAR T cell therapy currently undergoing Phase I clinical trials for the treatment of relapsed or refractory non-Hodgkin lymphoma, alongside ALLO-501A, which is in Phase I/II trials for large B-cell lymphoma and transformed follicular lymphoma.
In addition to its robust CAR T cell pipeline, Allogene is pioneering ALLO-715 for relapsed or refractory multiple myeloma and ALLO-605 for multiple myeloma treatment. The company's expansive portfolio extends further with ALLO-647, an anti-CD52 monoclonal antibody, and other promising candidates targeting renal cell cancer, immune checkpoint inhibitors, small cell lung cancer, and aggressive neuroendocrine tumors. Allogene's strategic collaborations with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc., along with its partnership with The University of Texas MD Anderson Cancer Center, highlight its commitment to advancing cutting-edge therapies through collaborative research and development efforts.
Founded in 2017, Allogene Therapeutics has rapidly emerged as a leader in the field, leveraging its deep scientific expertise and strategic alliances to accelerate the development of next-generation cancer treatments. The company's headquarters in the heart of California's biotechnology hub underscores its access to pioneering research and talent, positioning it at the forefront of innovation in immuno-oncology. With a steadfast dedication to transforming cancer care through novel therapies, Allogene is poised to make significant strides in improving outcomes and quality of life for patients worldwide.
Driven by a mission to harness the power of cellular immunotherapy, Allogene Therapeutics continues to push the boundaries of cancer treatment with a focus on scalability, accessibility, and efficacy. By advancing its pipeline of allogeneic CAR T cell therapies and strategic initiatives, the company remains committed to reshaping the landscape of oncology care and delivering hope to patients and their families facing the challenges of cancer.